Transgene SA (OTCMKTS:TRGNF – Get Free Report)’s stock price was down 46.2% during mid-day trading on Tuesday . The stock traded as low as $0.70 and last traded at $0.70. Approximately 425 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 433 shares. The stock had previously closed at $1.30.
Transgene Stock Down 46.2 %
The company has a 50 day moving average price of $1.54 and a 200-day moving average price of $1.57.
About Transgene
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Transgene
- Profitably Trade Stocks at 52-Week Highs
- Shares of RH Down Nearly 40%: Where Investors Can Turn To Now
- Where Do I Find 52-Week Highs and Lows?
- Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian
- 3 Best Fintech Stocks for a Portfolio Boost
- Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
